Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Sociodemographic characteristics Diagnosis (vitamin B12 deficiency or pernicious anaemia), age, sex, education level, employment status, country of residence (England, Wales, Scotland, Northern Ireland, Republic of Ireland), region of residence (nine English regions, according to the Office for National Statistics, Wales, Scotland, and Northern Ireland) were assessed using the questions in Supplementary Table S1
Abstract Treatment with a nicotinamide N-methyltransferase inhibitor (NNMTi
RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
The aggregated results show structural and biomechanical improvements in four tissues: muscle, tendon, ligament, and bone
You and your colleagues are just so busy
US$ 24.70
US$ 21.33
US$ 29.37
.png)
